Kura Oncology Announces Acceptance of Two Abstracts for Presentation at AACR Annual Meeting
March 14 2023 - 5:32PM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer, today announced
that two abstracts have been accepted for presentation at the
upcoming American Association for Cancer Research (AACR) Annual
Meeting, to be held in Orlando from April 14-19, 2023.
“We look forward to presenting preclinical data supporting the
combination of farnesyl transferase inhibitors (FTIs) with KRASG12C
inhibitors and tyrosine kinase inhibitors at this year’s AACR
Annual Meeting,” said Troy Wilson, Ph.D., J.D., President and Chief
Executive Officer of Kura Oncology. “These data add to the emerging
body of evidence supporting the potential to use FTIs as
combination agents to prevent or delay emergence of resistance to
certain classes of targeted therapy. We recently announced FDA
clearance of the Investigational New Drug application for our
next-generation farnesyl transferase inhibitor, KO-2806, which was
designed to improve upon potency, pharmacokinetic and
physicochemical properties of earlier FTI drug candidates, and we
look forward to initiating our FIT-001 Phase 1 trial with KO-2806
later this year.”
Session titles and information for the two abstracts are listed
below and are now available on the AACR online itinerary
planner.
Combination of tipifarnib with
KRASG12C inhibitors to prevent
adaptive resistance Session Category / Title: Clinical
Research Excluding Trials / Precision Molecular Subtyping and
Therapeutic DevelopmentSession Date and Time: Sunday, April 16,
2023; 1:30 PM - 5:00 PM ETLocation: Orange County Convention
Center, Poster Section 43 Abstract / Poster: 1079 / 23
Tipifarnib synergizes with TKIs in clear cell renal cell
carcinoma models Session Category / Title: Clinical
Research Excluding Trials / Precision Molecular Subtyping and
Therapeutic DevelopmentSession Date and Time: Sunday, April 16,
2023; 1:30 PM - 5:00 PM ETLocation: Orange County Convention
Center, Poster Section 43Abstract / Poster: 1071 / 15
Copies of the presentations will be available on Kura's website
at https://kuraoncology.com/pipeline/#posters_and_presentations
following presentation at the meeting.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. The Company’s pipeline consists of small
molecule drug candidates that target cancer signaling pathways.
Ziftomenib is a once-daily, oral drug candidate targeting the
menin-KMT2A protein-protein interaction for the treatment of
genetically defined AML patients with high unmet need. The Company
is currently enrolling patients in a Phase 2 registration-directed
trial (KOMET-001) of ziftomenib in NPM1-mutant relapsed or
refractory AML. Kura is preparing to initiate multiple Phase 1
trials to evaluate ziftomenib in combination with current standards
of care in earlier lines of therapy and across multiple patient
populations, including NPM1-mutant and KMT2A-rearranged AML.
Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2
trial (KURRENT-HN) in combination with alpelisib for patients with
PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a
next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001)
as a monotherapy and in combination with other targeted therapies
in adult patients with advanced solid tumors. For additional
information, please visit Kura’s website at
www.kuraoncology.com.
Forward-Looking Statements
This news release contains certain forward-looking statements
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include statements
regarding, among other things, the efficacy, safety and therapeutic
potential of tipifarnib and KO-2806, and progress and expected
timing of Kura’s drug development programs. Factors that may cause
actual results to differ materially include the risk that compounds
that appeared promising in early research or clinical trials do not
demonstrate safety and/or efficacy in later preclinical studies or
clinical trials, the risk that Kura may not obtain approval to
market its product candidates, uncertainties associated with
performing clinical trials, regulatory filings, applications and
other interactions with regulatory bodies, risks associated with
reliance on third parties to successfully conduct clinical trials,
the risks associated with reliance on outside financing to meet
capital requirements, and other risks associated with the process
of discovering, developing and commercializing drugs that are safe
and effective for use as human therapeutics, and in the endeavor of
building a business around such drugs. You are urged to consider
statements that include the words “may,” “will,” “would,” “could,”
“should,” “believes,” “estimates,” “projects,” “promise,”
“potential,” “expects,” “plans,” “anticipates,” “intends,”
“continues,” “designed,” “goal,” or the negative of those words or
other comparable words to be uncertain and forward-looking. For a
further list and description of the risks and uncertainties the
Company faces, please refer to the Company's periodic and other
filings with the Securities and Exchange Commission, which are
available at www.sec.gov. Such forward-looking statements are
current only as of the date they are made, and Kura assumes no
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise.
Contacts
Investors: Pete De Spain Senior Vice President, Investor
Relations & Corporate Communications(858) 500-8803
pete@kuraoncology.com
Media:Alexandra WeingartenSenior Manager, Corporate
Communications(858) 500-8822alexandra@kuraoncology.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2023 to Apr 2024